Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

31
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
31
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

700
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
700
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stem Cell Transplantation in Friedreich Ataxia: Cure for Leukemia but No Effect on Neurological Progression.

Annals of clinical and translational neurology·2026
Same author

Advances in Gene and Cellular Therapy in Friedreich Ataxia.

Molecular diagnosis & therapy·2026
Same author

Compound Heterozygote Friedreich Ataxia Patients With Covert Proximal FXN Gene Deletions.

Annals of clinical and translational neurology·2026
Same author

Domain Specific Placebo Response in the Modified Friedreich's Ataxia Rating Scale.

Annals of clinical and translational neurology·2025
Same author

Genetic and Phenotypic Variability in Siblings With Friedreich Ataxia.

Neurology. Genetics·2025
Same author

Automated Deep Learning-based Segmentation of the Dentate Nucleus Using Quantitative Susceptibility Mapping MRI.

Radiology. Artificial intelligence·2025

Related Experiment Video

Updated: Sep 6, 2025

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

11.8K

Friedreich ataxia: clinical features and new developments.

Medina Keita1, Kellie McIntyre1, Layne N Rodden1

  • 1Departments of Pediatrics & Neurology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Neurodegenerative Disease Management
|June 29, 2022
PubMed
Summary

Friedreich

Keywords:
FrataxinNRF2antioxidantclinical care guidelineclinical trialmultisystem

More Related Videos

A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
07:33

A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia

Published on: May 21, 2010

36.2K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.7K

Related Experiment Videos

Last Updated: Sep 6, 2025

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

11.8K
A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
07:33

A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia

Published on: May 21, 2010

36.2K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.7K

Area of Science:

  • Neuroscience
  • Genetics
  • Clinical Medicine

Background:

  • Friedreich's ataxia (FRDA) is a rare neurodegenerative disorder affecting 1 in 50,000-100,000 individuals in the USA.
  • FRDA presents with ataxia and neurological deficits, alongside cardiac, orthopedic, and endocrine dysfunctions.
  • Developing disease-specific clinical care guidelines is crucial due to FRDA's multifaceted nature.

Purpose of the Study:

  • To review recent advancements in Friedreich's ataxia research.
  • To highlight emerging therapeutic strategies and a deeper understanding of the disease's pathology.
  • To discuss new insights into FRDA's neuroanatomy and developmental aspects.

Main Methods:

  • Review of recent scientific literature and clinical trial data.
  • Analysis of novel findings in gene silencing patterns.
  • Examination of updated neuroanatomical studies.

Main Results:

  • Clinical drug trials targeting the NRF2 pathway and frataxin restoration are advancing.
  • A variegated gene silencing pattern in FRDA offers new therapeutic insights.
  • Refined understanding of FRDA neuroanatomy and developmental features aids in targeting interventions.

Conclusions:

  • Recent developments in FRDA research offer promising therapeutic avenues.
  • Novel insights into gene silencing and neuroanatomy will refine treatment strategies.
  • Continued research is essential for improving clinical care and therapeutic outcomes for FRDA patients.